FibroGen Inc (FGEN)

Currency in USD
9.480
-0.400(-4.05%)
Closed·
9.430-0.050(-0.53%)
·
FGEN Scorecard
Full Analysis
Operates with a significant debt burden
FGEN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
9.0509.940
52 wk Range
4.50021.938
Key Statistics
Prev. Close
9.48
Open
9.85
Day's Range
9.05-9.94
52 wk Range
4.5-21.938
Volume
52.37K
Average Volume (3m)
51.54K
1-Year Change
4.58%
Book Value / Share
-55.17
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
FGEN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
43.000
Upside
+353.59%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

FibroGen Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

FibroGen Inc Company Profile

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

FibroGen Inc Earnings Call Summary for Q2/2025

  • FibroGen reports Q2 2025 EPS of -$1.88, missing forecast of -$0.09; revenue falls short at $1.3M vs $2.88M expected
  • Stock drops 3.9% to $8.71 post-earnings; company valued at $34M market cap, deemed overvalued by InvestingPro analysis
  • Operating costs decrease 72% YoY; R&D expenses down 82%; company extends cash runway to 2028
  • Full-year 2025 revenue guidance set at $6M-$8M; Phase II trial for prostate cancer treatment FG3246 to begin Q3 2025
  • CEO expresses optimism about clinical programs; CFO highlights financial strategies to benefit shareholders
Last Updated: 11/08/2025, 22:46
Read Full Transcript

Compare FGEN to Peers and Sector

Metrics to compare
FGEN
Peers
Sector
Relationship
P/E Ratio
−0.4x−1.2x−0.5x
PEG Ratio
0.00−0.050.00
Price/Book
−0.2x2.7x2.6x
Price / LTM Sales
5.2x8.3x3.3x
Upside (Analyst Target)
353.6%301.3%40.6%
Fair Value Upside
Unlock15.6%5.3%Unlock

Analyst Ratings

1 Buy
1 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 43.000
(+353.59% Upside)

Earnings

Latest Release
Aug 11, 2025
EPS / Forecast
-1.88 / -0.09
Revenue / Forecast
1.35M / 2.88M
EPS Revisions
Last 90 days

FGEN Income Statement

People Also Watch

20.30
SRPT
-0.49%
6.1700
CYN
-4.49%
5.35
REPL
+5.11%
139.23
CRCL
-9.10%
2.45
INMB
-4.30%

FAQ

What Stock Exchange Does FibroGen Inc Trade On?

FibroGen Inc is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for FibroGen Inc?

The stock symbol for FibroGen Inc is "FGEN."

What Is the FibroGen Inc Market Cap?

As of today, FibroGen Inc market cap is 38.34M.

What Is FibroGen Inc's Earnings Per Share (TTM)?

The FibroGen Inc EPS (TTM) is -0.51.

From a Technical Analysis Perspective, Is FGEN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has FibroGen Inc Stock Split?

FibroGen Inc has split 1 times.

How Many Employees Does FibroGen Inc Have?

FibroGen Inc has 225 employees.

What is the current trading status of FibroGen Inc (FGEN)?

As of 15 Aug 2025, FibroGen Inc (FGEN) is trading at a price of 9.48, with a previous close of 9.48. The stock has fluctuated within a day range of 9.05 to 9.94, while its 52-week range spans from 4.50 to 21.94.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.